PD-1 Pandemonium at the American Association for Cancer Research Annual Meeting

Oncologist. 2019 May;24(5):571-573. doi: 10.1634/theoncologist.2019-0281.

Abstract

This editorial describes the results of discussions between the U.S. FDA Oncology Center of Excellence and members of six pharmaceutical companies—a forum aptly named PD‐1 Pandemonium—regarding development and regulatory approvals of immune checkpoint inhibitors.

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Congresses as Topic
  • Drug Approval*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / immunology
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology
  • United States
  • United States Food and Drug Administration

Substances

  • Antineoplastic Agents, Immunological
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor